KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block


Por: Garcia-Robledo, JE, Rosell, R, Ruiz-Patino, A, Sotelo, C, Arrieta, O, Zatarain-Barron, L, Ordonez, C, Jaller, E, Rojas, L, Russo, A, de Miguel-Perez, D, Rolfo, C and Cardona, AF

Publicada: 1 ene 2022
Resumen:
Non-small-cell lung cancer (NSCLC) is a heterogeneous disease, and therapeutic management has advanced to identify various critical oncogenic mutations that promote lung cancer tumorigenesis. Subsequent studies have developed targeted therapies against these oncogenes in the hope of personalized treatment based on the tumor's molecular genomics. This review presents a comprehensive review of the biology, new therapeutic interventions, and resistance patterns of two well-defined subgroups, tumors with KRAS and MET alterations. We also discuss the status of molecular testing practices for these two key oncogenic drivers, considering the progressive introduction of next-generation sequencing (NGS) and RNA sequencing in regular clinical practice.

Filiaciones:
Garcia-Robledo, JE:
 Mayo Clin, Div Hematol Oncol, Scottsdale, AZ USA

:
 Quiron Dexeus Univ Inst, Canc Biol & Precis Med Program, Germans Trias & Pujol Res Inst IGTPI, Dr Rosell Oncol Inst IOR, Barcelona, Spain

Ruiz-Patino, A:
 Fdn Clin & Appl Canc Res FICMAC, Bogota, Colombia

 Univ el Bosque, Mol Oncol & Biol Syst Res Grp FOX G, Bogota, Colombia

Sotelo, C:
 Fdn Clin & Appl Canc Res FICMAC, Bogota, Colombia

 Univ el Bosque, Mol Oncol & Biol Syst Res Grp FOX G, Bogota, Colombia

Arrieta, O:
 Natl Canc Inst INCan, Thorac Oncol Unit, Mexico City, DF, Mexico

 Natl Canc Inst INCan, Personalized Oncol Lab, Mexico City, DF, Mexico

Zatarain-Barron, L:
 Natl Canc Inst INCan, Thorac Oncol Unit, Mexico City, DF, Mexico

 Natl Canc Inst INCan, Personalized Oncol Lab, Mexico City, DF, Mexico

Ordonez, C:
 Fdn Clin & Appl Canc Res FICMAC, Bogota, Colombia

 Univ el Bosque, Mol Oncol & Biol Syst Res Grp FOX G, Bogota, Colombia

Jaller, E:
 Univ El Bosque, Dept Internal Med, Bogota, Colombia

Rojas, L:
 Fdn Clin & Appl Canc Res FICMAC, Bogota, Colombia

 Clin Colsanitas, Dept Clin Oncol, Bogota, Colombia

 Clin Country, Clin & Translat Oncol Grp, Bogota, Colombia

Russo, A:
 AO Papardo, Med Oncol Unit, Messina, Italy

 Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA

de Miguel-Perez, D:
 Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA

Rolfo, C:
 Univ Maryland, Sch Med, Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA

Cardona, AF:
 Luis Carlos Sarmiento Angulo Canc Treatment & Res, Direct Res & Educ, Bogota, Colombia

 Fdn Clin & Appl Canc Res FICMAC, Bogota, Colombia

 Univ el Bosque, Mol Oncol & Biol Syst Res Grp FOX G, Bogota, Colombia
ISSN: 17534658





Therapeutic Advances in Respiratory Disease
Editorial
SAGE Publications, 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND, Reino Unido
Tipo de documento: Review
Volumen: 16 Número:
Páginas:
WOS Id: 000751857200001
ID de PubMed: 35098800
imagen gold, Green Published

MÉTRICAS